MedTrace Logo

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

NCT03603275 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2022-08-25

No results posted yet for this study

Summary

This US study aims to assess hemophilia A patient characteristics and reasons for switching from both patient/caregiver and physician perspectives. For this purpose, this research study will include hemophilia A patients who have switched from an existing therapy to Kovaltry or Jivi. In doing so, real world evidence will be obtained from both patient and physician perspectives offering key insights for effective therapeutic management of patients with hemophilia A and to more fully understand what drives patient switching from a patient perspective and a physician perspective.

Conditions

Interventions

DRUG

New FVIII products

Kovaltry or Jivi prescribed by the treating Physician

Sponsors & Collaborators

  • American Thrombosis and Hemostasis Network

    collaborator NETWORK

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-06
Primary Completion
2020-05-14
Completion
2020-05-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603275 on ClinicalTrials.gov